Effect of tyrosine kinase inhibitors on male fertility in patients with chronic phase chronic myeloid leukemia.
George NesrSimone ClaudianiDragana MilojkovicAndrew InnesFiona FernandoIrene CaballesPatience MungoziRichard SzydloSilvia LovatoChanna JayasenaJane ApperleyPublished in: Leukemia & lymphoma (2024)
Advancements in the management of patients with chronic myeloid leukemia (CML) allowed them to achieve survival comparable with their healthy counterparts. Consequently, their care has widened with growing focus on quality of life, including parenting children. Although tyrosine kinase inhibitors (TKI) are contraindicated in pregnancy given their teratogenic effect, their effect on male fertility is less clear with contradictory results from animal studies and case reports/series. We compared the sperm analysis parameters, as the gold-standard assessment for male fertility, of 11 patients with CP- CML before and after TKI therapy. Median therapy duration was 5.1 years (range: 2.5-16.5). The sperm concentration, % progressive, and total motility before and after therapy were not significantly different ( p = 0.376, 0.569, and 0.595, respectively). Our results suggest no impairment in fertility potential in male patients after TKI therapy. A larger sample size is crucial to support/refute our findings.
Keyphrases
- chronic myeloid leukemia
- end stage renal disease
- healthcare
- tyrosine kinase
- multiple sclerosis
- chronic kidney disease
- escherichia coli
- newly diagnosed
- young adults
- prognostic factors
- preterm birth
- case report
- risk assessment
- pregnant women
- staphylococcus aureus
- bone marrow
- advanced non small cell lung cancer
- epidermal growth factor receptor